Biotech Values

[DewDiligence]

(ENTA)—Blurb from ABBV’s GS webcast about speed of enrollment in phase-3 HCV trials (from 6/13/13):

http://seekingalpha.com/article/1501302-abbvie-s-management-presents-at-goldman-sachs-34th-annual-global-healthcare-conference-transcript

Jami Rubin (GS analyst): How is the Phase 3 enrollment going and when will we start to see that data read out?

William Chase (CFO): …let me just say we are extremely pleased with the way enrollment is going. I have been in Abbott [AbbVie] for 16 years, I was involved in HIV development at a time when patients were looking for those therapies. I have never seen things enroll this quickly. We are on track for a mid- 2014 [NDA] filing.